El-Dirany, R.; Fernández-Rubio, C.; Peña-Guerrero, J.; Moreno, E.; Larrea, E.; Espuelas, S.; Abdel-Sater, F.; Brandenburg, K.; MartÃnez-de-Tejada, G.; Nguewa, P.
Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis. Pharmaceutics 2022, 14, 2528.
https://doi.org/10.3390/pharmaceutics14112528
AMA Style
El-Dirany R, Fernández-Rubio C, Peña-Guerrero J, Moreno E, Larrea E, Espuelas S, Abdel-Sater F, Brandenburg K, MartÃnez-de-Tejada G, Nguewa P.
Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis. Pharmaceutics. 2022; 14(11):2528.
https://doi.org/10.3390/pharmaceutics14112528
Chicago/Turabian Style
El-Dirany, Rima, Celia Fernández-Rubio, José Peña-Guerrero, Esther Moreno, Esther Larrea, Socorro Espuelas, Fadi Abdel-Sater, Klaus Brandenburg, Guillermo MartÃnez-de-Tejada, and Paul Nguewa.
2022. "Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis" Pharmaceutics 14, no. 11: 2528.
https://doi.org/10.3390/pharmaceutics14112528
APA Style
El-Dirany, R., Fernández-Rubio, C., Peña-Guerrero, J., Moreno, E., Larrea, E., Espuelas, S., Abdel-Sater, F., Brandenburg, K., MartÃnez-de-Tejada, G., & Nguewa, P.
(2022). Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis. Pharmaceutics, 14(11), 2528.
https://doi.org/10.3390/pharmaceutics14112528
